These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 16500392)

  • 1. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
    Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of infliximab maintenance therapy on health-related quality of life.
    Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR
    Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal healing in Crohn's disease: what you see is what you get?
    Mahadevan U
    Gastrointest Endosc; 2006 Mar; 63(3):443-4. PubMed ID: 16500393
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
    Rutgeerts P; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Hanauer SB
    Gastroenterology; 2004 Feb; 126(2):402-13. PubMed ID: 14762776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.